21 results about "Immunoglobulin region" patented technology

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates to the field of antibody proteins, in particular to an immunoglobulin Fc dimer with a stable disulfide bond, an Fc fusion protein containing the Fc protein dimer and a calculation design method of the Fc fusion protein. The immunoglobulin Fc protein dimer comprises two protein subunits, a CH3 structural domain of each subunit contains at least one cysteine mutation, and the two protein subunits are combined through an interchain disulfide bond formed by mutation cysteine. Cysteine mutation is specifically introduced into the CH3 structural domain of the Fc region of the immunoglobulin to form a stable interchain disulfide bond, so that the problem of insufficient stability of the Fc protein dimer is solved.

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Provided are an immunoglobulin Fc region-based heterodimeric Fc stent, a heterologous multimeric protein containing the heterodimeric Fc stent, in particular a single or multispecific binding protein, and a composition comprising same and a use.

The invention provides a preparation method of a recombinant protein for improving retinal oxidative stress. The recombinant protein comprises an immunoglobulin Fc region and a functional structure domain, and the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The preparation method comprises the following steps: connecting polynucleotide for coding the recombinant protein to an expression vector to construct a recombinant expression vector; and transferring the recombinant expression vector into an expression cell, and carrying out induced expression, separation and purification to obtain the recombinant protein. According to the preparation method, the recombinant protein with high soluble expression and enhanced stability can be obtained.

Provided herein are methods for treating or preventing leukemia and myelodysplasia disorders comprising a multifunctional binding protein comprising a first antigen-binding domain and a second antigen-binding domain and all or part of an immunoglobulin Fc region or variant thereof wherein the first antigen-binding domain specifically binds to CD123, and the second antigen-binding domain specifically binds to CD123, and all or part of an immunoglobulin Fc region or variant thereof. And the second antigen-binding domain specifically binds to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof binds to a human Fc-gamma receptor.

Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant.

Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.

The present invention relates to a pharmaceutical composition comprising a protein complex, and its pharmaceutical applications for treating or preventing conditions characterized by impaired leukocyte production, such as neutropenia. The protein complex can also be formed by linking an immunoglobulin Fc region to a bioactive polypeptide via a non-peptide polymer linked to the immunoglobulin Fc region. [Solution] The present invention provides a method for treating chemotherapy-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient, and a method for treating radiation-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient.

The present invention relates to: a cosmetic composition for improving skin condition, a cosmetic composition for strengthening skin barrier, a pharmaceutical composition for preventing or treating atopic dermatitis, and a quasi-drug composition for preventing or ameliorating atopic dermatitis, each composition comprising, as active ingredient, a fusion protein comprising a CD300c protein or a fragment thereof and an immunoglobulin Fc region; and a method for treating atopic dermatitis by using the pharmaceutical composition. The compositions of the present invention have excellent effects of alleviating skin inflammation, reducing dead skin cells, strengthening skin barrier, alleviating xeroderma, and alleviating atopic dermatitis, and thus can be used as an effective therapeutic agent for atopic dermatitis.

A method of preparing a protein conjugate contains linking a mono-PEGylated immunoglobulin Fc region to a dual agonist exhibiting activity on both glucagon-like peptide-1 (GLP-1) and glucagon. The mono-PEGylated immunoglobulin Fc region is prepared by linking a linker of Formula 1 to the N-terminus of an immunoglobulin Fc region comprising a hinge sequence:CHO-L1-(OCH2CH2)nO-L2-R  [Formula 1].

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention provides a recombinant protein for improving retinal oxidative stress, which comprises an immunoglobulin Fc region and a functional structure domain, and the amino terminal of the functional structure domain is connected with the carboxyl terminal of the immunoglobulin Fc region; wherein the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The invention also provides a coding nucleic acid of the recombinant protein, an expression vector, a host cell, a pharmaceutical composition containing the recombinant protein and application of the pharmaceutical composition. The recombinant protein can remarkably reverse retinal cell injury caused by oxidative stress, and shows a strong protection or treatment effect.

Provided are a single domain antibody capable of binding to an immunoglobulin Fc region, an immunoglobulin Fc region binding protein comprising the one or more single domain antibodies, and a fusion protein comprising the single domain antibody and an Fc region.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

Provided are an immunoglobulin Fc region-based heterodimeric Fc stent, a heterologous multimeric protein containing the heterodimeric Fc stent, in particular a single or multispecific binding protein, and a composition comprising same and a use.

The invention provides an application of a recombinant protein in preparation of a medicine for preventing and / or treating eye diseases. The recombinant protein comprises an immunoglobulin Fc region and a functional structure domain, and the amino acid sequence of the functional structure domain is as shown in SEQ ID NO. 1. The recombinant protein can remarkably reverse retinal cell injury caused by oxidative stress, and shows a strong protection or treatment effect.

The present disclosure generally relates to conjugates, such as fusion proteins of one or more single domain antibodies or nanobodies and one or more immunoglobulin Fc regions, compositions comprising the same and methods of using such conjugates and compositions for the diagnosis, prevention, amelioration and treatment of noroviral infections.

To provide strong anti-BCMA therapies with manageable safety profiles.SOLUTION: Provided are multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof. The first ABD binding specifically to human BCMA, the second ABD binding specifically to human NKp46, and all or part of the immunoglobulin Fc region or variant thereof binding a human Fc-γ receptor. Also provided are methods for making said binding proteins, compositions thereof, and uses thereof, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).SELECTED DRAWING: None